Drugs / JNJ-67864238
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04102111 | Sep 2019 → Nov 2021 | Crohn disease | Janssen Research & Development, LLC | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-67864238 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04102111 ↗ |
| Route | Oral | “Participants will receive oral tablets of JNJ-67864238 twice daily.” NCT04102111 ↗ |